Ticlopidine is an oral antiplatelet medication belonging to the thienopyridine class. Its primary therapeutic role is to prevent the formation of abnormal blood clots in patients at risk for stroke or peripheral arterial disease. The drug works by irreversibly blocking the p2x12 adp receptor on platelets, which is essential for platelet aggregation. In the body Ticlopidine is converted to an active thiol metabolite that covalently modifies the receptor, preventing further adp signaling. This modification leads to a lasting reduction in platelet activation and thus a decrease in clot formation in cerebral and peripheral vessels. By limiting platelet aggregation the medication helps maintain blood flow through the brain and extremities, reducing the likelihood of ischemic events. The sustained inhibition of platelet function translates clinically into a lower risk of stroke and myocardial infarction in treated individuals. Overall Ticlopidine serves as a potent irreversible inhibitor of platelet adp receptors, providing antithrombotic protection through prolonged platelet suppression.

Ticlopidine is an antiplatelet medication that belongs to the thienopyridine class. It is prescribed to reduce the risk of stroke and myocardial infarction in patients with a history of cardiovascular disease. The drug works by irreversibly inhibiting the platelet adp receptor p2y12, which blocks a key pathway for platelet activation. This inhibition reduces the ability of platelets to aggregate, leading to a prolonged clotting time without affecting coagulation factors in the plasma. As a consequence, blood flow in cerebral and coronary vessels becomes less prone to occlusion, lowering the incidence of thrombotic events. Ticlopidine is administered orally in tablet form and its effect develops gradually over several days as platelet function is restored. Because the antiplatelet action is irreversible, the effect persists until new platelets are produced, typically requiring up to ten days to fully wear off. The overall pharmacological profile is characterized by metabolic activation to an active thiol metabolite that binds covalently to the target receptor.

Ticlopidine can increase the risk of bleeding by affecting platelet function. It may cause easy bruising or prolonged bleeding from cuts. Some users experience stomach discomfort or nausea. Skin reactions such as rash or itching have been reported. Headache and dizziness can occur in certain individuals. In rare cases, changes in blood counts or liver function tests may be observed.

Ticlopidine can cause gastrointestinal upset nausea and diarrhea. Some patients experience headache dizziness or fatigue. Rarely the drug may lead to low white blood cell count or anemia. Skin reactions such as rash itching or hives can occur. In isolated cases severe liver injury or allergic reactions have been reported. The medication may also affect taste sensation or cause dry mouth. These effects are generally mild and may resolve without intervention.